{"url_path":"/sec/rckt/8-k/2026-06-12/item-2-01","section_key":"item-2-01","section_title":"Item 2.01 Completion of Acquisition or Disposition of Assets.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1281895/0001140361-26-024997-index.html","accession_number":"0001140361-26-024997","cik":"0001281895","ticker":"RCKT","issuer_name":"ROCKET PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1281895/0001140361-26-024997-index.html","primary_entity_key":"0001281895","primary_entity_name":"ROCKET PHARMACEUTICALS, INC."},"word_count":330,"has_tables":true,"body_markdown":"Item 2.01.\n\nCompletion of Acquisition or Disposition of Assets.\n\nOn June 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric\nDisease Priority Review Voucher (“PRV”) to a large pharmaceutical company. The PRV was originally issued in connection with the FDA’s approval of the Company’s biologics license application for KRESLADI™ (marnetegragene autotemcel), an autologous\nhematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor\nfor allogeneic hematopoietic stem cell transplant.\n\nThe Asset Sale was completed pursuant to the terms of an asset purchase agreement, dated April 26, 2026 (the “PRV APA”). Pursuant to the PRV APA, the\nCompany received gross proceeds of $180.0 million from the buyer upon the closing of the Asset Sale.\n\nThe foregoing description of the PRV APA does not purport to be complete and is subject to, and qualified in its entirety, by the full text of the\nPRV APA, a copy of which will be filed with Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. The representations, warranties, covenants and agreements contained in the PRV APA were made only for the purposes of\nthe PRV APA and as of specific dates, are solely for the benefit of the parties to the PRV APA, and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures. The representations and warranties\nin the PRV APA were made for the purpose of allocating contractual risk between the parties to the PRV APA instead of establishing these matters as facts. Accordingly, the representations and warranties in the PRV APA are not intended to, and do\nnot, constitute representations and warranties to any person other than the parties to the PRV APA, including investors and security holders, and should not be relied upon as statements of factual information."}